Dermata Long Term Debt vs Short Term Debt Analysis

DRMA Stock

USD 1.45 0.12 7.64%

Dermata Therapeutics financial indicator trend analysis is much more than just examining Dermata Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Dermata Therapeutics is a good investment. Please check the relationship between Dermata Therapeutics Long Term Debt and its Short Term Debt accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dermata Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade Dermata Stock refer to our How to Trade Dermata Stock guide.

Long Term Debt vs Short Term Debt

Long Term Debt vs Short Term Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Dermata Therapeutics Long Term Debt account and Short Term Debt. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Dermata Therapeutics' Long Term Debt and Short Term Debt is -0.37. Overlapping area represents the amount of variation of Long Term Debt that can explain the historical movement of Short Term Debt in the same time period over historical financial statements of Dermata Therapeutics, assuming nothing else is changed. The correlation between historical values of Dermata Therapeutics' Long Term Debt and Short Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Long Term Debt of Dermata Therapeutics are associated (or correlated) with its Short Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Term Debt has no effect on the direction of Long Term Debt i.e., Dermata Therapeutics' Long Term Debt and Short Term Debt go up and down completely randomly.

Correlation Coefficient

-0.37

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Long Term Debt

Long-term debt is a debt that Dermata Therapeutics has held for over one year. Long-term debt appears on Dermata Therapeutics balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Dermata Therapeutics balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Short Term Debt

Most indicators from Dermata Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Dermata Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dermata Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade Dermata Stock refer to our How to Trade Dermata Stock guide.The current year's Issuance Of Capital Stock is expected to grow to about 6.9 M, whereas Selling General Administrative is forecasted to decline to about 3.5 M.

	2021	2022	2023	2024 (projected)
Interest Expense	45.6K	63.6K	57.2K	111.4K
Depreciation And Amortization	14.1K	9.7K	8.0M	8.4M

Interest Expense Depreciation And Amortization

Dermata Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Long Term Debt	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Short Long Term Debt	Total Current Assets	Net Working Capital	Short Term Debt	Common Stock
Total Assets		0.73	0.8	-0.44	0.95	0.95	-0.41	-0.98	-0.74	0.76	1.0	0.71	-0.41	1.0	-0.32	0.47	0.96	0.87	-0.74	1.0	0.73	0.72	1.0	0.99	0.72	-0.93
Short Long Term Debt Total	0.73		0.25	0.14	0.78	0.78	-0.39	-0.64	-0.77	0.54	0.72	0.38	-0.39	0.72	-0.32	0.49	0.81	0.87	-0.28	0.76	0.95	1.0	0.73	0.64	1.0	-0.82
Other Current Liab	0.8	0.25		-0.58	0.65	0.65	-0.29	-0.83	-0.39	0.71	0.82	0.72	-0.29	0.82	-0.38	0.35	0.62	0.51	-0.66	0.77	0.26	0.24	0.8	0.83	0.24	-0.59
Total Current Liabilities	-0.44	0.14	-0.58		-0.44	-0.44	0.14	0.57	0.28	-0.56	-0.45	-0.12	0.14	-0.45	-0.01	-0.13	-0.41	-0.32	0.91	-0.41	0.1	0.15	-0.44	-0.58	0.15	0.39
Total Stockholder Equity	0.95	0.78	0.65	-0.44		1.0	-0.59	-0.96	-0.9	0.79	0.95	0.49	-0.59	0.95	-0.42	0.63	0.97	0.95	-0.77	0.96	0.84	0.78	0.95	0.93	0.78	-1.0
Net Tangible Assets	0.95	0.78	0.65	-0.44	1.0		-0.6	-0.96	-0.9	0.8	0.95	0.48	-0.6	0.95	-0.43	0.63	0.97	0.95	-0.77	0.96	0.84	0.78	0.95	0.93	0.78	-1.0
Current Deferred Revenue	-0.41	-0.39	-0.29	0.14	-0.59	-0.6		0.5	0.82	-0.55	-0.41	0.1	1.0	-0.41	0.89	-0.95	-0.41	-0.59	0.33	-0.4	-0.6	-0.37	-0.41	-0.36	-0.37	0.61
Net Debt	-0.98	-0.64	-0.83	0.57	-0.96	-0.96	0.5		0.77	-0.81	-0.98	-0.63	0.5	-0.98	0.39	-0.54	-0.94	-0.86	0.82	-0.97	-0.68	-0.63	-0.98	-0.99	-0.63	0.93
Retained Earnings	-0.74	-0.77	-0.39	0.28	-0.9	-0.9	0.82	0.77		-0.77	-0.73	-0.11	0.82	-0.73	0.65	-0.86	-0.81	-0.93	0.61	-0.75	-0.87	-0.76	-0.74	-0.7	-0.76	0.92
Accounts Payable	0.76	0.54	0.71	-0.56	0.79	0.8	-0.55	-0.81	-0.77		0.77	0.2	-0.55	0.77	-0.6	0.72	0.71	0.84	-0.75	0.73	0.52	0.52	0.76	0.79	0.52	-0.78
Cash	1.0	0.72	0.82	-0.45	0.95	0.95	-0.41	-0.98	-0.73	0.77		0.71	-0.41	1.0	-0.33	0.47	0.96	0.86	-0.74	1.0	0.72	0.71	1.0	0.99	0.71	-0.92
Non Current Assets Total	0.71	0.38	0.72	-0.12	0.49	0.48	0.1	-0.63	-0.11	0.2	0.71		0.1	0.71	0.07	-0.11	0.59	0.31	-0.28	0.71	0.33	0.38	0.71	0.68	0.38	-0.44
Long Term Debt	-0.41	-0.39	-0.29	0.14	-0.59	-0.6	1.0	0.5	0.82	-0.55	-0.41	0.1		-0.41	0.89	-0.95	-0.41	-0.59	0.33	-0.4	-0.6	-0.37	-0.41	-0.36	-0.37	0.61
Cash And Short Term Investments	1.0	0.72	0.82	-0.45	0.95	0.95	-0.41	-0.98	-0.73	0.77	1.0	0.71	-0.41		-0.33	0.47	0.96	0.86	-0.74	1.0	0.72	0.71	1.0	0.99	0.71	-0.92
Common Stock Shares Outstanding	-0.32	-0.32	-0.38	-0.01	-0.42	-0.43	0.89	0.39	0.65	-0.6	-0.33	0.07	0.89	-0.33		-0.94	-0.23	-0.48	0.13	-0.3	-0.46	-0.29	-0.32	-0.26	-0.29	0.44
Non Current Liabilities Total	0.47	0.49	0.35	-0.13	0.63	0.63	-0.95	-0.54	-0.86	0.72	0.47	-0.11	-0.95	0.47	-0.94		0.45	0.69	-0.35	0.45	0.64	0.47	0.47	0.42	0.47	-0.65
Other Current Assets	0.96	0.81	0.62	-0.41	0.97	0.97	-0.41	-0.94	-0.81	0.71	0.96	0.59	-0.41	0.96	-0.23	0.45		0.92	-0.75	0.97	0.82	0.81	0.96	0.95	0.81	-0.97
Other Stockholder Equity	0.87	0.87	0.51	-0.32	0.95	0.95	-0.59	-0.86	-0.93	0.84	0.86	0.31	-0.59	0.86	-0.48	0.69	0.92		-0.67	0.87	0.88	0.86	0.87	0.84	0.86	-0.97
Total Liab	-0.74	-0.28	-0.66	0.91	-0.77	-0.77	0.33	0.82	0.61	-0.75	-0.74	-0.28	0.33	-0.74	0.13	-0.35	-0.75	-0.67		-0.72	-0.32	-0.28	-0.74	-0.83	-0.28	0.74
Net Invested Capital	1.0	0.76	0.77	-0.41	0.96	0.96	-0.4	-0.97	-0.75	0.73	1.0	0.71	-0.4	1.0	-0.3	0.45	0.97	0.87	-0.72		0.76	0.76	1.0	0.98	0.76	-0.94
Property Plant And Equipment Gross	0.73	0.95	0.26	0.1	0.84	0.84	-0.6	-0.68	-0.87	0.52	0.72	0.33	-0.6	0.72	-0.46	0.64	0.82	0.88	-0.32	0.76		0.95	0.73	0.64	0.95	-0.87
Short Long Term Debt	0.72	1.0	0.24	0.15	0.78	0.78	-0.37	-0.63	-0.76	0.52	0.71	0.38	-0.37	0.71	-0.29	0.47	0.81	0.86	-0.28	0.76	0.95		0.72	0.63	1.0	-0.81
Total Current Assets	1.0	0.73	0.8	-0.44	0.95	0.95	-0.41	-0.98	-0.74	0.76	1.0	0.71	-0.41	1.0	-0.32	0.47	0.96	0.87	-0.74	1.0	0.73	0.72		0.99	0.72	-0.93
Net Working Capital	0.99	0.64	0.83	-0.58	0.93	0.93	-0.36	-0.99	-0.7	0.79	0.99	0.68	-0.36	0.99	-0.26	0.42	0.95	0.84	-0.83	0.98	0.64	0.63	0.99		0.63	-0.9
Short Term Debt	0.72	1.0	0.24	0.15	0.78	0.78	-0.37	-0.63	-0.76	0.52	0.71	0.38	-0.37	0.71	-0.29	0.47	0.81	0.86	-0.28	0.76	0.95	1.0	0.72	0.63		-0.81
Common Stock	-0.93	-0.82	-0.59	0.39	-1.0	-1.0	0.61	0.93	0.92	-0.78	-0.92	-0.44	0.61	-0.92	0.44	-0.65	-0.97	-0.97	0.74	-0.94	-0.87	-0.81	-0.93	-0.9	-0.81

Click cells to compare fundamentals

Dermata Therapeutics Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

MSFT	Microsoft
V	Visa Class A
MSFT	Microsoft

When determining whether Dermata Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dermata Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dermata Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dermata Therapeutics Stock:

How To Invest In Dermata

Details

Is Dermata Stock a good investment?

Details

What is Dermata Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dermata Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade Dermata Stock refer to our How to Trade Dermata Stock guide.

You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dermata Therapeutics. If investors know Dermata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dermata Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(17.30)

Return On Assets

(0.91)

Return On Equity

(1.73)

The market value of Dermata Therapeutics is measured differently than its book value, which is the value of Dermata that is recorded on the company's balance sheet. Investors also form their own opinion of Dermata Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dermata Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dermata Therapeutics' market value can be influenced by many factors that don't directly affect Dermata Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Dermata Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dermata Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dermata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Dermata Long Term Debt vs Short Term Debt Analysis

Long Term Debt vs Short Term Debt

Long Term Debt vs Short Term Debt Correlation Analysis

Correlation Coefficient

Long Term Debt

Short Term Debt

Dermata Therapeutics fundamental ratios Correlations

Dermata Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Short Long Term Debt	+ 1.0	Short Long Term Debt Total
Short Term Debt	+ 1.0	Short Long Term Debt Total

Common Stock	- 1.0	Net Tangible Assets
Common Stock	- 1.0	Total Stockholder Equity
Net Working Capital	- 0.99	Net Debt
Total Current Assets	- 0.98	Net Debt
Cash And Short Term Investments	- 0.98	Net Debt
Cash	- 0.98	Net Debt